Does Amphotericin B Liposome Interact with Repository Corticotropin?
CDI records a moderate classification for Amphotericin B Liposome and Repository Corticotropin. The stored summary is: Concurrent use may potentiate hypokalemia, which could predispose patient to cardiac dysfunction. Serum electrolytes and cardiac function should be closely monitored. The mechanism involves potentiation of hypokalemia. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Amphotericin B Liposome Class
- Lipid-based Polyene Antifungal
- Repository Corticotropin Class
- Adrenocorticotropic Hormone
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Potentiation of hypokalemia
What To Tell Your Doctor or Pharmacist
If you are taking Amphotericin B Liposome and your doctor is considering prescribing Repository Corticotropin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider